

# Chronic liver disease assessment in HIV mono-infected individuals: HeAL (HIV non-viral Liver disease) Study Update

Harriet Sharp<sup>1,2</sup>, Dev Katarey<sup>1,2</sup>, Laura Vickers<sup>2</sup>, Bethany Parnell<sup>2</sup>, Jonathan Potts<sup>2</sup>, Sumitra Verma<sup>1,2</sup>, Yvonne Gilleece<sup>1,2</sup>

<sup>1</sup>Brighton and Sussex Medical School, Brighton, UK

<sup>2</sup>Brighton and Sussex University Hospital NHS Trust, Brighton, UK

## Introduction

- Chronic liver disease (CLD) is a major cause of morbidity and mortality in people living with HIV (PLWH)
- Following advances in viral hepatitis treatment, future CLD is likely to be due to non-viral aetiologies
- Potential contributors include
  - Alcohol
  - Metabolic syndrome
  - Antiretrovirals

## Aims

Investigate the prevalence and predictors of CLD in PLWH with abnormal liver function

## Methods

- Inclusion criteria:
  - PLWH
  - Negative viral hepatitis serology
  - Elevated transaminases over 6 months
- Consenting individuals prospectively assessed by:
  - AUDIT questionnaire
  - Screening for metabolic syndrome
  - Transient elastography (Fibroscan<sup>®</sup>)
- Study definitions
  - Significant hepatic steatosis (SHS): controlled attenuation parameter (CAP)  $\geq 237$  dB/m
  - Significant hepatic fibrosis (SHF) liver stiffness measurement (LSM)  $\geq 7.1$  kPa
  - Cirrhosis: LSM  $\geq 11.5$  kPa

## Results

- Of 429 eligible individuals, 237 recruited since 2015
  - Mean age  $52.3 \pm 9.6$  years,
  - 92.8% male,
  - 96.6% with undetectable viral load,
  - Mean HIV duration  $15.8 \pm 7.5$  years
- Overall prevalence of SHS was 63% (n=149), and SHF was 21% (n=49), of whom 36 (73%) had SHS and 18 (37%) had cirrhosis.
- On binary logistic regression, HDL and AUDIT score were significantly associated with SHF whereas CD4 baseline, HIV duration, BMI, hypertension, diabetes, and duration on ARV were not.
- Predictors of SHS included BMI, HDL and AUDIT score.
- No classical risk factors were identified in 8 (16%) individuals with SHF but they had significantly shorter HIV duration and higher peak ALT compared to those with risk factors for SHF (Table 1).

	No risk factors n=8	Risk factors n=41	Significance
Age (years)	45.5 $\pm$ 9.6	52.6 $\pm$ 9.7	P=0.069
HIV duration (years)	9.1 $\pm$ 4.5	16.0 $\pm$ 7.5	P=0.006*
Baseline CD4 (10 <sup>6</sup> /L)	421 $\pm$ 240	425 $\pm$ 649	P=0.407
ALT peak (iu/L)	112.6 $\pm$ 79.6	70.2 $\pm$ 40.2	P=0.048*

## Conclusions

- There is high liver disease burden in PLWH with elevated transaminases; nearly 2/3 having SHS and 1/5 SHF.
- MS risk factors and alcohol use appear to predict both SHS and SHF
- However, one sixth of individuals with SHF have no identifiable classical risk factors
- This raises the real possibility of immune dysregulation or direct hepatotoxicity of HIV

## Recommendations

- Screening strategies for CLD in PLWH alone should be considered to ensure timely Hepatology input
- Emphasis to be placed upon appropriate counselling regarding alcohol intake and weight loss for these individuals